non-small cell lung cancer cell line

Olomoucine is an ATP-competitive inhibitor of Cdk2 cyclin A, Cdc2 CyclinB, CDK2 CyclinE, CDK5 p35, and ERK1 p44 MAP kinase with IC50s of 7, 7, 7, 3, and 25 µM, respectively. It regulates the cell cycle and exhibits anti-melanin tumor activities.

EGFR-IN-59 is an EGFR inhibitor with an IC50 value of 190 nM and an all-time apoptosis inducer. EGFR-IN-59 exhibited cytotoxicity against a non-small lung cancer cell line (A549) and normal lung fibroblasts (WI38) with IC50s of 8.62 and 52.6 μM, respectively. EGFR-IN-59 EGFR-IN-59 can be used to study a variety of cancers including non-small cell lung cancer (NSCLC), head and neck cancer, breast cancer and colorectal cancer.

FJ9 is a FZD7 inhibitor which disrupts protein-protein interaction between Frz7 and the PDZ domain of DVL, and induces apoptosis in melanoma cell line and non-small cell lung cancer cell line.

RKS262 is a specific cyclin CDK inhibitor. RKS262 was identified by structural optimization of Nifurtimox which is currently undergoing phase II clinical trials to treat high-risk neuroblastoma. In a NCI(60) cell-line assay RKS262 exhibited significant cytotoxicity in ovarian cancer cells and a variety of other cell lines exceeding effects of commercial drugs such as cisplatin, 5-FU, cyclophosphamide or sapacitabine. Various leukemia cell-lines were most sensitive (GI(50): ~ 10 nM) while several non-small cell lung cancer cell lines and few cell lines from other tissues were relatively resistant (GI(50) > 1 µM) to RKS262 treatment.

NSD3-IN-3, a potent inhibitor of NSD3, demonstrates significant anticancer activity by inhibiting the growth and proliferation of the non-small cell lung cancer cell line H460, with an IC50 value of 1.86 μM.

EGFRkinase inhibitor 7 (compound 18i) is an EGFR inhibitor with an IC50 of 42.3 nM, exhibiting anticancer properties. This compound demonstrates significant in vitro cytotoxicity and capacity to induce apoptosis. Furthermore, EGFRkinase inhibitor 7 displays anti-proliferative activity against human colon cancer cell line HCT116 and human non-small cell lung cancer cell line A549, with IC50 values of 4.82 µM and 1.43 µM, respectively.

Agatharesinol acetonide shows anticancer activity towards the A549 non-small-cell lung-cancer cell line (IC50 = 27.1 microM).